# ACS Antithrombotic Selection

Select antithrombotic therapy in acute coronary syndrome by matching invasive timing, ischemic risk, bleeding risk, age, and chronic anticoagulation needs to an initial DAPT and anticoagulation strategy, then deliberately plan post-PCI aspirin withdrawal, P2Y12 choice, and treatment duration.

**Clinical question:** How should antiplatelet and anticoagulant therapy be selected and modified across acute coronary syndrome presentation, PCI, and discharge?

Updated: 2026-09-15T17:45:29.462992+00:00

## What matters in practice
- Treat confirmed ACS initially with antiplatelet therapy plus parenteral anticoagulation; anticoagulation usually ends after the acute hospitalization unless another indication requires long-term oral anticoagulation. [9]
- For NSTE-ACS, immediate angiography is indicated for hemodynamic instability, refractory ischemia, acute heart failure from ongoing ischemia, life-threatening arrhythmia or arrest, mechanical complications, or recurrent dynamic ischemic ECG changes. [9]
- In ACS patients without high bleeding risk, administer DAPT for at least 12 months; ticagrelor monotherapy beginning at least 1 month after PCI is a guideline-supported bleeding-reduction option. [2][23]
- For PCI patients requiring long-term oral anticoagulation, stop aspirin 1 to 4 weeks after PCI and continue an oral anticoagulant plus a P2Y12 inhibitor, preferably clopidogrel. [2][23]
- Avoid prasugrel after prior stroke or TIA; consider maintenance-dose reduction in patients aged 75 years or older or weighing less than 60 kg. [3]
- In NSTE-ACS patients aged 70 years or older, clopidogrel was noninferior to ticagrelor or prasugrel in POPular AGE and is a practical alternative when bleeding risk is prominent. [1][23]

## Choose the acute pathway before committing to an oral P2Y12 strategy

Cath-laboratory timing determines whether P2Y12 pretreatment is useful or avoidable.

Treat patients with ACS using initial antiplatelet therapy plus parenteral anticoagulation while defining the revascularization plan. In patients without a separate indication for long-term oral anticoagulation, discontinue anticoagulation after the acute hospitalization rather than continuing it as routine secondary prevention. [9]

Send NSTE-ACS directly to immediate invasive coronary angiography when any very-high-risk feature is present: hemodynamic instability or cardiogenic shock, recurrent or ongoing chest pain refractory to medical therapy, acute heart failure thought due to ongoing ischemia, life-threatening arrhythmia or cardiac arrest after presentation, mechanical complication, or recurrent dynamic ischemic ECG changes. These features override routine biomarker-based observation. [9]

For NSTE-ACS without an immediate angiography indication, use a validated 0/1-hour or 0/2-hour NSTEMI rule-in/rule-out algorithm. Pursue angiography within 24 hours when NSTEMI is confirmed, GRACE score exceeds 140, transient ST-segment elevation occurs, or dynamic ST-segment/T-wave changes are present. [9]

Do not routinely pretreat a patient with NSTE-ACS with an oral P2Y12 inhibitor when an early invasive strategy is planned and coronary anatomy is not yet known. This avoids committing the patient to potent platelet inhibition before defining PCI need, CABG candidacy, or a noncoronary diagnosis. [14][15]
- Elevated cardiac markers, ischemic ST-T changes, age over 65 years, TIMI score of 5 or greater, and clinical instability identify a higher-risk NSTE-ACS phenotype that supports aggressive antithrombotic and invasive management. [12]
- Troponin positivity is a risk-stratification signal in NSTE-ACS and should increase urgency for an invasive evaluation when integrated with ECG findings and clinical instability. [5][12]

*Angiography timing determines the immediate antithrombotic sequence in NSTE-ACS. [9][14]*

| Clinical branch | Trigger | Next action | Antithrombotic implication |
| --- | --- | --- | --- |
| Immediate invasive pathway | Shock, refractory ischemia, ischemic acute heart failure, malignant arrhythmia/cardiac arrest, mechanical complication, or recurrent dynamic ischemic ECG changes [9] | Immediate invasive coronary angiography with revascularization as indicated [9] | Begin antiplatelet therapy and parenteral anticoagulation; avoid a routine anatomy-blind P2Y12 pretreatment strategy in NSTE-ACS. [9][14] |
| Early invasive pathway | Confirmed NSTEMI, GRACE score >140, transient ST elevation, or dynamic ST/T-wave changes [9] | Angiography within 24 hours [9] | Select P2Y12 therapy in the context of the invasive plan and subsequent revascularization decision. [9][14] |
| Rule-out/rule-in pathway | No immediate invasive indication [9] | Apply a 0/1-hour or 0/2-hour NSTEMI algorithm [9] | Do not let empiric P2Y12 pretreatment replace serial diagnostic risk stratification. [9][14] |

## Match P2Y12 inhibitor potency to ischemic protection, bleeding risk, and contraindications

The default ACS strategy favors potent platelet inhibition, but patient-level exceptions are consequential.

For ACS after coronary stent implantation, ticagrelor is reasonable in preference to clopidogrel for maintenance P2Y12 therapy. Contemporary guidance continues to frame DAPT with aspirin plus ticagrelor or prasugrel as the standard antiplatelet approach for many ACS patients during the first year, particularly when bleeding risk is not high. [13][22][23]

Do not administer prasugrel to a patient with prior stroke or TIA. For patients aged 75 years or older or weighing less than 60 kg, consider reducing the prasugrel maintenance dose; these two characteristics should prompt an explicit reassessment of whether prasugrel's ischemic benefit justifies bleeding exposure. [3]

Use clopidogrel as the preferred P2Y12 inhibitor when chronic oral anticoagulation is required after PCI. Clopidogrel is also a reasonable alternative when bleeding risk, adverse effects, or cost limit ticagrelor or prasugrel, including in older patients. [2][23]

In POPular AGE, patients aged 70 years or older with NSTE-ACS assigned to clopidogrel had noninferior outcomes compared with ticagrelor or prasugrel; the trial population had a mean age of 77 years. This evidence supports clopidogrel selection when advanced age and bleeding susceptibility outweigh the anticipated incremental ischemic protection from a potent P2Y12 inhibitor. [1][23]
- If bleeding, adverse effects, or cost emerge after initial ticagrelor or prasugrel treatment, switching to clopidogrel may be considered after 1 month; this carries a weaker recommendation because definitive ischemic-safety evidence is limited. [23]
- Do not use platelet-function-guided switching from prasugrel to clopidogrel as a routine strategy to improve net outcomes after ACS PCI; ANTARCTIC and TROPICAL-ACS did not show additional benefit over 12-month prasugrel-based DAPT. [6]

*P2Y12 inhibitor selection should identify contraindications and competing bleeding risk before discharge. [1][2][3][23]*

| Patient feature | Preferred practical choice | Avoid or modify | Reason |
| --- | --- | --- | --- |
| ACS after PCI, no high bleeding risk | DAPT with aspirin plus ticagrelor or prasugrel when suitable [22][23] | Do not shorten therapy solely for convenience during the early high-risk phase. [22][23] | Guidelines support at least 12 months of DAPT in ACS patients who are not at high bleeding risk. [23] |
| Prior stroke or TIA | Select a non-prasugrel P2Y12 strategy [3] | Prasugrel is contraindicated. [3] | Prior cerebrovascular ischemia is a Class 3 contraindication to prasugrel. [3] |
| Age ≥75 years or weight <60 kg | If prasugrel is used, consider maintenance-dose reduction; consider clopidogrel when bleeding risk predominates. [3][1][23] | Do not treat potent P2Y12 therapy as automatically preferred. [1][3][23] | Prasugrel dose modification is advised for these characteristics, and clopidogrel was noninferior in older NSTE-ACS patients. [1][3][23] |
| Long-term oral anticoagulation required | Clopidogrel with oral anticoagulation after early aspirin discontinuation [2][23] | Avoid prolonged triple therapy unless a short initial period is justified. [19][23] | Guidelines prefer clopidogrel in this setting; aspirin adds bleeding after the early period. [2][19][23] |

## Plan DAPT duration and aspirin withdrawal at discharge

The discharge prescription should specify the intended duration and the trigger for modification.

For ACS patients who are not at high bleeding risk, prescribe DAPT for at least 12 months. Use low-dose aspirin during DAPT; the ACC/AHA focused update recommends 81 mg daily, with an acceptable range of 75 to 100 mg daily. [13][23]

For a patient who has tolerated ticagrelor-based DAPT after PCI and in whom bleeding reduction is a priority, transition to ticagrelor monotherapy no earlier than 1 month after PCI. This pathway preserves potent P2Y12 inhibition while removing aspirin exposure. [2][23]

Do not equate all abbreviated regimens. Current commentary on the 2025 guideline states that abbreviated clopidogrel or prasugrel monotherapy is not recommended after ACS PCI: shorter clopidogrel regimens have increased MI compared with 12-month treatment, and abbreviated prasugrel-monotherapy safety remains inconclusive. [23]

If a patient initially receives ticagrelor or prasugrel, reassess at 1 month for clinically important bleeding, drug intolerance, or unaffordability. A switch to clopidogrel after 1 month may be considered, but frame it as a tradeoff with less robust evidence for ischemic equivalence than standard therapy. [23]
- Prescribe a proton pump inhibitor in ACS patients on antiplatelet therapy who are at risk for gastrointestinal bleeding. [2]
- Avoid routine platelet-function testing to select a de-escalation regimen after ACS PCI. [6]
- Document whether the patient is high bleeding risk before choosing abbreviated therapy; DAPT individualization requires explicit comparison of bleeding and ischemic risk. [14][15]

### Why the first month changes the decision

The incremental ischemic benefit of ticagrelor or prasugrel over clopidogrel is concentrated early after ACS, whereas excess bleeding accrues later. This temporal separation supports reassessment after the first month rather than an indiscriminate early switch to clopidogrel. [22]

*Post-PCI antiplatelet pathways after ACS. [2][13][23]*

| Clinical situation | Antiplatelet plan | Timing rule | Key limitation |
| --- | --- | --- | --- |
| No high bleeding risk | DAPT with aspirin plus a P2Y12 inhibitor [13][23] | Continue for at least 12 months. [23] | Use aspirin 81 mg daily during DAPT. [13] |
| Tolerated ticagrelor DAPT; bleeding mitigation needed | Stop aspirin and continue ticagrelor alone [2][23] | Transition at ≥1 month after PCI. [2][23] | This recommendation applies to ticagrelor monotherapy, not abbreviated clopidogrel or prasugrel monotherapy. [23] |
| Bleeding, adverse effects, or cost on potent P2Y12 treatment | Consider switching ticagrelor or prasugrel to clopidogrel [23] | Consider after 1 month. [23] | Recommendation strength is limited by inconclusive ischemic-outcome evidence. [23] |

## Minimize triple therapy when chronic oral anticoagulation is required

The pivotal choice is when to remove aspirin, not whether to omit all antiplatelet therapy.

In ACS patients undergoing PCI who require long-term oral anticoagulation, discontinue aspirin 1 to 4 weeks after PCI and continue the oral anticoagulant plus a P2Y12 inhibitor, preferably clopidogrel. This is the preferred U.S. guideline pathway for reducing ongoing bleeding exposure while maintaining antithrombotic protection. [2][23]

A short triple-therapy interval may be used for 7 to 30 days, followed by oral anticoagulation plus clopidogrel. In the AUGUSTUS population of patients with atrial fibrillation and recent ACS or PCI receiving a planned P2Y12 inhibitor, apixaban plus a P2Y12 inhibitor reduced bleeding compared with vitamin K antagonist therapy, while aspirin increased bleeding without an overall efficacy advantage. [19][23]

Use the first 30 days to individualize aspirin duration. In AUGUSTUS, aspirin versus placebo through approximately 30 days increased severe bleeding from 1.1% to 2.1% while reducing severe ischemic events from 2.6% to 1.7%; after 30 days, aspirin increased bleeding from 2.5% to 3.7% without a significant reduction in ischemic events. [19]
- When anticoagulation is not required long term, do not extend acute parenteral anticoagulation beyond hospitalization as a routine ACS strategy. [9]
- If gastrointestinal bleeding risk is present during combination antithrombotic therapy, add a proton pump inhibitor. [2]

*Antithrombotic sequence for ACS PCI with a long-term oral anticoagulation indication. [2][19][23]*

| Time after PCI | Regimen | Decision point |
| --- | --- | --- |
| Initial 7-30 days | Oral anticoagulant plus clopidogrel plus aspirin when a short triple-therapy period is selected [23] | Balance early ischemic protection against bleeding; aspirin benefit-risk is most plausible during the earliest period. [19] |
| 1-4 weeks onward | Stop aspirin; continue oral anticoagulant plus clopidogrel [2][23] | This is the preferred strategy for ongoing therapy after PCI. [2][23] |
| Beyond 30 days | Avoid continuing aspirin routinely with oral anticoagulant plus P2Y12 inhibitor [19] | Aspirin increased bleeding without significant ischemic-event reduction after 30 days in AUGUSTUS. [19] |

## Reassess ischemic events, bleeding, and treatment feasibility at every transition

A stable discharge regimen should not be treated as a fixed 12-month prescription.

At discharge, document the indication for each antithrombotic agent, the intended aspirin stop date, the intended P2Y12 duration, and whether long-term oral anticoagulation is required. This prevents inadvertent prolonged triple therapy and makes the 1-month reassessment actionable. [2][19][23]

Escalate urgently to invasive reassessment for recurrent or ongoing ischemic chest pain refractory to medical treatment, recurrent dynamic ischemic ECG changes, acute heart failure presumed due to ongoing ischemia, hemodynamic instability, life-threatening arrhythmia, cardiac arrest, or mechanical complications. These are immediate angiography triggers even after an initially less urgent pathway. [9]

When bleeding occurs, first identify whether aspirin can be withdrawn under an established pathway rather than reflexively stopping all antiplatelet therapy. Ticagrelor monotherapy at 1 month or later after PCI is the guideline-supported aspirin-withdrawal option for patients who have tolerated DAPT; in patients requiring oral anticoagulation, aspirin discontinuation at 1 to 4 weeks with continued clopidogrel is preferred. [2][23]
- For patients at gastrointestinal bleeding risk, use a proton pump inhibitor during antiplatelet treatment. [2]
- Do not use a prior aspirin-related bleeding event as a reason to continue triple therapy beyond the short early period; aspirin's bleeding liability persists after 30 days in anticoagulated ACS/PCI patients. [19]
- If a potent P2Y12 inhibitor becomes unsustainable after the first month because of bleeding, adverse effects, or cost, consider clopidogrel rather than unplanned antiplatelet discontinuation. [23]

*Transition checklist for antithrombotic therapy after ACS. [2][9][19][23]*

| Transition | Required decision | Action |
| --- | --- | --- |
| ED to cath pathway | Is there a very-high-risk feature? | If yes, proceed to immediate angiography; if no, use a 0/1-hour or 0/2-hour NSTEMI algorithm and identify high-risk criteria for angiography within 24 hours. [9] |
| PCI to discharge | Does the patient need chronic oral anticoagulation? | If yes, prescribe clopidogrel with oral anticoagulation and define aspirin discontinuation at 1 to 4 weeks. [2][23] |
| One-month review | Has bleeding, intolerance, or cost changed treatment feasibility? | For tolerated ticagrelor after PCI, consider ticagrelor monotherapy; consider a switch to clopidogrel when potent P2Y12 therapy cannot be maintained. [2][23] |

## References
1. Clopidogrel versus ticagrelor or prasugrel in patients aged 70 years or older with non-ST-elevation acute coronary syndrome (POPular AGE): the randomised, open-label, non-inferiority trial — www.thelancet.com — https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(20)30325-1/fulltext
2. 2025 Acute Coronary Syndromes Guideline-at-a-Glance | JACC — www.jacc.org — https://www.jacc.org/doi/full/10.1016/j.jacc.2025.01.018
3. Antiplatelet and Anticoagulant Therapy in the 2025 ACC ... — www.jacc.org — https://www.jacc.org/doi/10.1016/j.jacc.2025.04.002
4. ACC/AHA Versus ESC Guidelines on Dual Antiplatelet ... — www.jacc.org — https://www.jacc.org/doi/10.1016/j.jacc.2018.09.057
5. Troponin: an important prognostic marker and risk-stratification tool in non–ST-segment elevation acute coronary syndromes | JACC — www.jacc.org — https://www.jacc.org/doi/10.1016/S0735-1097%2802%2902832-2
6. Antiplatelet De-Escalation Strategies in Patients Undergoing Percutaneous Coronary Intervention | Circulation: Cardiovascular Interventions — www.ahajournals.org — https://www.ahajournals.org/doi/10.1161/CIRCINTERVENTIONS.123.013263?url_ver=Z39.88-2003&rfr_id=ori%3Arid%3Acrossref.org&rfr_dat=cr_pub++0pubmed
7. Demystifying the Contemporary Role of 12-Month Dual Antiplatelet Therapy After Acute Coronary Syndrome — www.ahajournals.org — https://www.ahajournals.org/doi/10.1161/CIRCULATIONAHA.124.069012?doi=10.1161%2FCIRCULATIONAHA.124.069012
8. Early anticoagulation in the current management of NSTE-ACS: Evidence, guidelines, practice and perspectives - ScienceDirect — www.sciencedirect.com — https://www.sciencedirect.com/science/article/pii/S0167527318311781
9. ‘10 commandments’ for the 2023 ESC Guidelines for the management of acute coronary syndromes | European Heart Journal | Oxford Academic — academic.oup.com — https://academic.oup.com/eurheartj/article/45/14/1193/7516285
10. Seeking for the boundaries of de-escalation in antiplatelet therapy for acute coronary syndrome | European Heart Journal - Cardiovascular Pharmacotherapy | Oxford Academic — academic.oup.com — https://academic.oup.com/ehjcvp/advance-article/doi/10.1093/ehjcvp/pvaf070/8258576
11. Dual Antiplatelet Therapy De-escalation Strategies — www.sciencedirect.com — https://www.sciencedirect.com/science/article/abs/pii/S0002914920313473
12. Pharmacoinvasive management of acute coronary syndrome: incorporating the 2007 ACC/AHA guidelines: the CATH (cardiac catheterization and antithrombotic therapy in the hospital) Clinical Consensus Panel Report--III - PubMed — www.ncbi.nlm.nih.gov — http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Abstract&list_uids=18180524
13. 2016 ACC/AHA Guideline Focused Update on Duration of Dual Antiplatelet Therapy in Patients With Coronary Artery Disease: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines — www.acc.org — https://www.acc.org/~/media/Non-Clinical/Files-PDFs-Excel-MS-Word-etc/Tools%20and%20Practice%20Support/Quality%20Programs/Anticoag-10-14/DAPT/1%20Levine%202016%20DAPT%20Guidelines.pdf?la=en
14. 2020 ESC NSTE-ACS Guidelines: Evolving Approaches and Recommendations - American College of Cardiology — www.acc.org — https://www.acc.org/Latest-in-Cardiology/Articles/2021/05/20/13/01/2020-ESC-NSTE-ACS-Guidelines
15. 2020 ESC NSTE-ACS Guidelines: Evolving Approaches and ... — www.acc.org — https://www.acc.org/latest-in-cardiology/articles/2021/05/20/13/01/2020-esc-nste-acs-guidelines
16. 2018 ESC/EACTS Guidelines on myocardial revascularization — uat.ajnr.org — https://uat.ajnr.org/lookup/external-ref?access_num=10.1093%2Feurheartj%2Fehy394&link_type=DOI
17. ESC 365 - Pattern of dual antiplatelet use and 12-month outcomes stratified by bleeding and ischemic risk in acute coronary syndrome patients undergoing percutaneous coronary intervention — esc365.escardio.org — https://esc365.escardio.org/presentation/266796
18. ESC 365 - Ticagrelor versus clopidogrel in acute coronary syndrome patients with concurrent high ischemic and high bleeding risk after drug-eluting stent implantation — esc365.escardio.org — https://esc365.escardio.org/presentation/328682
19. Antithrombotic Therapy After Acute Coronary Syndrome or PCI in Atrial Fibrillation - American College of Cardiology — www.acc.org — https://www.acc.org/latest-in-cardiology/clinical-trials/2019/03/15/18/40/augustus
20. 10. Cardiovascular Disease and Risk Management: Standards of ... — diabetesjournals.org — https://diabetesjournals.org/care/article/48/Supplement_1/S207/157549/10-Cardiovascular-Disease-and-Risk-Management
21. Non‐vitamin K antagonist oral anticoagulants (NOACs) post ... — www.cochranelibrary.com — https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD013252.pub2/full
22. De-Escalation of Dual Antiplatelet Therapy in Patients With Acute Coronary Syndromes — www.jacc.org — https://www.jacc.org/doi/10.1016/j.jacc.2021.06.012
23. Perspective on the Choice and Duration of Dual Antiplatelet Therapy Recommendations in the 2025 Acute Coronary Syndrome Management Guideline — www.jacc.org — https://www.jacc.org/doi/10.1016/j.jacc.2025.04.045
24. Short Duration of DAPT Versus De-Escalation After Percutaneous Coronary Intervention for Acute Coronary Syndromes — www.jacc.org — https://www.jacc.org/doi/10.1016/j.jcin.2021.11.028

## Editorial note

Prepared from cited clinical literature using Astra's research workflow. Verify recommendations against current guidance and patient-specific factors.